Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcturus Therapeutics Holdings (ARCT) Liabilities and Shareholders Equity (2018 - 2025)

Arcturus Therapeutics Holdings (ARCT) has disclosed Liabilities and Shareholders Equity for 8 consecutive years, with $271.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Liabilities and Shareholders Equity fell 21.19% year-over-year to $271.1 million, compared with a TTM value of $1.2 billion through Dec 2025, down 21.52%, and an annual FY2025 reading of $271.1 million, down 21.19% over the prior year.
  • Liabilities and Shareholders Equity was $271.1 million for Q4 2025 at Arcturus Therapeutics Holdings, down from $282.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $481.5 million in Q1 2021 and bottomed at $271.1 million in Q4 2025.
  • Average Liabilities and Shareholders Equity over 5 years is $384.3 million, with a median of $390.7 million recorded in 2021.
  • The sharpest move saw Liabilities and Shareholders Equity soared 567.74% in 2021, then crashed 32.43% in 2022.
  • Year by year, Liabilities and Shareholders Equity stood at $392.8 million in 2021, then increased by 14.66% to $450.4 million in 2022, then decreased by 4.66% to $429.4 million in 2023, then fell by 19.87% to $344.1 million in 2024, then decreased by 21.19% to $271.1 million in 2025.
  • Business Quant data shows Liabilities and Shareholders Equity for ARCT at $271.1 million in Q4 2025, $282.3 million in Q3 2025, and $309.3 million in Q2 2025.